Brain & Nervous System Multiple Sclerosis Treatment Rebif for Treating Multiple Sclerosis What you need to know about this interferon medication By Julie Stachowiak, PhD Julie Stachowiak, PhD Facebook Julie Stachowiak, PhD, is the author of the Multiple Sclerosis Manifesto, the winner of the 2009 ForeWord Book of the Year Award, Health Category. Learn about our editorial process Updated on March 22, 2021 Medically reviewed by David Ozeri, MD Medically reviewed by David Ozeri, MD LinkedIn David Ozeri, MD, is a board-certified rheumatologist from Tel Aviv, Israel specializing in arthritis, autoimmune diseases, and biologic therapies. Learn about our Medical Expert Board Print Table of Contents View All Table of Contents Indications Effectiveness Administration Pros and Cons Side Effects Considerations Cost Rebif (interferon beta 1-a) is an injectable prescription drug for treating multiple sclerosis (MS), a disease in which your immune system damages the protective covering of your nerves (myelin sheath). Your body naturally makes a type of anti-inflammatory called interferon. Rebif mimics those interferons and helps lessen the inflammation caused by the immune system's attack on your nerves that occurs with MS. SDI Productions / Getty Images Indications Rebif is one of several disease-modifying therapies for treating relapsing-remitting MS (RRMS). Like other interferon therapies, Rebif can lower your number of relapses by about a third and delay some of the physical disability associated with the disease. Types of MS Effectiveness Numerous studies show that Rebif is an effective treatment for many people with RRMS. The drug tends to fare well in comparison studies, too. In a review of studies comparing interferon-beta to glatiramer acetate, the drug in Copaxone, researchers concluded that outcomes showed only small differences in most measures. Interferon-beta did appear to limit the increase of lesions on the brain better than glatiramer acetate, though. A comparison study of interferon beta-1a and dimethyl fumarate (the drug in Tecfidera) suggested comparable relapse outcomes, but better safety outcomes for interferon beta-1a. When put up against alemtuzumab (the drug in Lemtrada) in two 2017 studies, though, researchers say interferon beta-1a didn't come out on top. One study said alemtuzumab led to fewer relapses, slower disease progression, and fewer new lesions. The other suggested that alemtuzumab improved physical, mental, and emotional quality of life measures significantly more than interferon beta-1a. Scientists may have discovered why, for some people, Rebif becomes less effective over time. Research published in 2018 suggests that some people may develop antibodies to interferon beta-1a, which impairs the drug's function. The likelihood of antibodies was higher in participants who'd taken the drug for more than two years. In addition, these people tended to be sicker than those who tested negative for the antibodies. How Multiple Sclerosis Is Treated Administration Rebif is an injectable medication delivered subcutaneously (under the skin) three times per week. It's available in a prefilled syringe as well as two different types of autoinjectors. Dosing options are 22 micrograms (mcg) and 44 mcg. A titration pack offers an 8.8-mcg dose for those who are advised to start at a lower dosage and gradually work up to 22 or 44 mcg. (This can help minimize side effects.) Pros and Cons The are several pros and cons to weigh when considering Rebif for your MS. Pros Requires the use of tiny needles (less needle pain) Subcutaneous injections (less painful than deeper types) Convenient dosing options (no mixing) Doesn't need to be kept cold Cons Low pH (may hurt more when injected) More frequent dosing (3x weekly vs. 1x weekly) When you're on Rebif, you'll need to have regular bloodwork to check for low blood cell counts and liver problems, and you'll also need to be monitored closely for depression. However, most MS treatments require regular monitoring for possible complications. Side Effects The potential side effects of Rebif are similar to those of other interferon-based therapies. Common side effects include:Flu-like symptoms, such as fever, chills, sweating, muscle aches, and fatigue lasting for eight hours or longerChanges in liver blood tests, which can include liver failure; symptoms include nausea, loss of appetite, fatigue, dark urine, pale stools, yellowing of the skin or whites of your eye, confusion, and bleeding easilyStomach pain Other serious side effects are possible. Contact your healthcare provider if you experience any of the following: Depression, suicidal thoughts, or other mood problemsSeizuresBlood problems due to changes in bone marrow, which can lead to infections and problems with bleeding and bruisingInjection-site problems, including redness, pain, swelling, fluid drainage, necrosis (dying skin that turns blue or black); rotating injection sites can help prevent this problemSerious allergic and skin reactions (rare), with symptoms such as itching; swelling of the face, eyes, lips, tongue, or throat; trouble breathing; anxiety; feeling faint; rashes or hives; sores in the mouth; skin that blisters and peels Possible side effects should be part of the risks/benefits weighing that you and your healthcare provider go through when considering treatments. Considerations and Contraindications It may not be safe for someone with a seizure disorder to take Rebif. Women who are pregnant should not use this drug. Animal studies have found that it can harm fetuses. Let your healthcare provider know if you get pregnant while taking this drug. If you want to get pregnant, your practitioner may have you stop taking Rebif for one to three months before you begin trying to conceive. You also should not breastfeed while taking Rebif. Your healthcare provider may want to take certain health issues into consideration before prescribing this medication, such as any history of mental illness, liver problems, and alcohol use. Cost As with most MS medications, Rebif is expensive—about $5,150 per month. Your insurance company may cover it, so be sure to check. Additionally, the manufacturer has programs that may be able to help you afford the drug. To discuss options, you can call the company at 1-877-447-3243 or visit their website. A Word From Verywell This is a lot of information to take in, and good treatment decisions are crucial. That's why it's important for you to do your research, discuss options with your healthcare team, and let your healthcare provider know how things are going once you start treatment. It's all part of finding the treatments that work best for you. Sources Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy. Arroyo Gonzalez R, Kita M, Crayton H, et al. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Mult Scler. 2017 Sep;23(10):1367-1376. doi: 10.1177/1352458516677589. Ernst FR, Barr P, Elmor R, Wong SL. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon beta-1a or dimethyl fumarate: a real-world study. Curr Med Res Opin. 2017 Dec;33(12):2099-2106. doi: 10.1080/03007995.2017.1380616. La Mantia L, Di Pietrantonj C, Rovaris M, et al. Interferons-beta versus glatiriamer acetate for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2016 Nov 24;11:CD009333. doi: 10.1002/14651858.CD009333.pub3 Shokrollahi Barough M, Ashtari F, Sadat Akhavi M, et al. Neutralizing antibody production against Rebif and ReciGen in relapsing-remitting multiple sclerosis (RRMS) patients and its association with patient's disability. Int Immunopharmacol. 2018 Sep;62:109-113. doi: 10.1016/j.intimp.2018.06.032. Zhang J, Shi S, Zhang Y, et al. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2017 Nov 27;11:CD010968. doi: 10.1002/14651858.CD010968.pub2. By Julie Stachowiak, PhD Julie Stachowiak, PhD, is the author of the Multiple Sclerosis Manifesto, the winner of the 2009 ForeWord Book of the Year Award, Health Category. See Our Editorial Process Meet Our Medical Expert Board Share Feedback Was this page helpful? Thanks for your feedback! What is your feedback? Other Helpful Report an Error Submit